Comparative Pharmacology
Head-to-head clinical analysis: VASOSTRICT versus VAZCULEP.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VASOSTRICT versus VAZCULEP.
VASOSTRICT vs VAZCULEP
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Vasopressin is a synthetic analogue of the antidiuretic hormone (ADH) that acts on V1 receptors (vascular smooth muscle) to cause vasoconstriction, and on V2 receptors (renal collecting ducts) to increase water reabsorption. At high doses used in vasodilatory shock, it primarily increases systemic vascular resistance via V1 receptor activation.
Vazculep is a direct-acting vasoconstrictor that stimulates alpha-adrenergic receptors in vascular smooth muscle, causing peripheral vasoconstriction and increased blood pressure.
0.01-0.03 units/min IV continuous infusion, titrate to effect. Maximum 0.1 units/min.
5 mg IV bolus followed by 2.5 mg/hour continuous IV infusion; titrate to mean arterial pressure ≥65 mmHg. Maximum infusion rate: 40 mg/hour.
None Documented
None Documented
Terminal elimination half-life is approximately 10–20 minutes, with clinical effect terminated rapidly by enzymatic degradation (catechol-O-methyltransferase and monoamine oxidase) in the liver and other tissues.
Terminal elimination half-life is 12 hours. In patients with moderate renal impairment (CrCl 30-50 mL/min), half-life increases to 24 hours. Dose adjustment is recommended for CrCl <30 mL/min.
Primarily renal (90–95% as inactive metabolites); minor biliary/fecal excretion (<5%).
Renal excretion of unchanged drug accounts for 70% and fecal/biliary excretion accounts for 30%. Approximately 15% of the dose is excreted as glucuronide conjugate in urine.
Category C
Category C
Vasopressor
Vasopressor